Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
M Yi, X Zheng, M Niu, S Zhu, H Ge, K Wu - Molecular cancer, 2022 - Springer
Antibodies targeting programmed cell death protein-1 (PD-1) or its ligand PD-L1 rescue T
cells from exhausted status and revive immune response against cancer cells. Based on the …
cells from exhausted status and revive immune response against cancer cells. Based on the …
Harnessing cytokines and chemokines for cancer therapy
DJ Propper, FR Balkwill - Nature reviews Clinical oncology, 2022 - nature.com
During the past 40 years, cytokines and cytokine receptors have been extensively
investigated as either cancer targets or cancer treatments. A strong preclinical rationale …
investigated as either cancer targets or cancer treatments. A strong preclinical rationale …
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade
Abstract Treatment with combined immune checkpoint blockade (CICB) targeting CTLA-4
and PD-1 is associated with clinical benefit across tumor types, but also a high rate of …
and PD-1 is associated with clinical benefit across tumor types, but also a high rate of …
Immune-related adverse events of checkpoint inhibitors
M Ramos-Casals, JR Brahmer, MK Callahan… - Nature reviews Disease …, 2020 - nature.com
Cancer immunotherapies have changed the landscape of cancer treatment during the past
few decades. Among them, immune checkpoint inhibitors, which target PD-1, PD-L1 and …
few decades. Among them, immune checkpoint inhibitors, which target PD-1, PD-L1 and …
Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies
RJ Sullivan, JS Weber - Nature reviews Drug discovery, 2022 - nature.com
The immune-related adverse events associated with treatment with immune checkpoint
inhibitors result in significant morbidity for patients as well as considerable cost to the health …
inhibitors result in significant morbidity for patients as well as considerable cost to the health …
Immunosurveillance in clinical cancer management
The progression of cancer involves a critical step in which malignant cells escape from
control by the immune system. Antineoplastic agents are particularly efficient when they …
control by the immune system. Antineoplastic agents are particularly efficient when they …
Targeting cancer-promoting inflammation—have anti-inflammatory therapies come of age?
The immune system has crucial roles in cancer development and treatment. Whereas
adaptive immunity can prevent or constrain cancer through immunosurveillance, innate …
adaptive immunity can prevent or constrain cancer through immunosurveillance, innate …
Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy
Immunotherapies that target programmed cell death protein 1 (PD-1) and its ligand PD-L1
as well as cytotoxic T-lymphocyte-associated protein 4 (CTLA4) have shown impressive …
as well as cytotoxic T-lymphocyte-associated protein 4 (CTLA4) have shown impressive …
Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
Immune checkpoint inhibitor (ICI) therapy targeting anti-programmed cell death-1 (anti-PD-
1) or its ligand (anti-PD-L1) is the backbone of numerous combination regimens aimed at …
1) or its ligand (anti-PD-L1) is the backbone of numerous combination regimens aimed at …
Sex differences in immunity
NM Wilkinson, HC Chen, MG Lechner… - Annual review of …, 2022 - annualreviews.org
Strong epidemiological evidence now exists that sex is an important biologic variable in
immunity. Recent studies, for example, have revealed that sex differences are associated …
immunity. Recent studies, for example, have revealed that sex differences are associated …